Clinical Trial Update: Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness [Phase 3]

View source ↗

Summary

A Phase 3 trial of pitolisant for excessive daytime sleepiness in obstructive sleep apnea was withdrawn, with the study not proceeding.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Obstructive Sleep Apnea

Drugs mentioned

• Pitolisant (pitolisant)

Snippet

Sponsor: Bioprojet | Conditions: Excessive Daytime Sleepiness, Obstructive Sleep Apnea | Phase 3 | Status: WITHDRAWN